Table 1.

Characteristics of patients with SLE at the time of COVID-19 diagnosis (n=1922)

Characteristics	Mean (SD) or number (percentage)
Age, years, mean (SD)	44.4 (14.1)
Female, n (%)	1734 (90.4%)
Race/Ethnicity, n (%)
White	639 (33.3%)
Non-white	1102 (57.3%)
Missing	181 (9.4%)
Region, n (%)
Europe	543 (28.3%)
USA and Canada	555 (28.9%)
Latin America	643 (33.5%)
Other	181 (9.4%)
Time period, n (%)
<15 June 2020	733 (38.1%)
16 June–30 September 2020	444 (23.1%)
1 October 2020–12 April 2021	745 (38.8%)
Comorbidities, n (%)
0	1098 (57.1%)
1	511 (26.6%)
≥2	313 (16.3%)
Specific comorbidities, n (%)
Chronic renal insufficiency or ESRD	223 (11.8%)
Hypertension or cardiovascular disease	597 (31.1%)
Disease activity, n (%)
Remission	587 (30.5%)
Minimal or low	700 (36.4%)
Moderate	229 (11.9%)
Severe or high	77 (4.0%)
Missing	329 (17.1%)
Prednisone dose*, n (%)
0 mg/day	846 (44.0%)
1–5 mg/day	467 (24.3%)
6–9 mg/day	78 (4.1%)
≥10 mg/day	280 (14.6%)
Missing	251 (13.1%)
Medication category, n (%)
Antimalarials only	665 (34.6%)
No SLE therapy	230 (12.0%)
Oral synthetic drug monotherapy with methotrexate, leflunomide or sulfasalazine only†	175 (9.1%)
Oral synthetic drug monotherapy with (mycophenolate/mycophenolic acid, tacrolimus, cyclophosphamide, ciclosporin or azathioprine)†	630 (32.8%)
Biologic/Targeted synthetic monotherapy	45 (2.3%)
Biologic/Targeted and immunosuppressive drug combination therapy†	177 (9.2%)

*All glucocorticoids were converted to prednisone-equivalent doses.

†These patients could be also on antimalarials.

ESRD, end-stage renal disease; SLE, systemic lupus erythematosus.